Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMK7HFI)

Drug Name
Mefenamic acid Drug Info
Synonyms
ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
4044
ChEBI ID
CHEMBL686
CAS Number
CAS 61-68-7
TTD Drug ID
D05FTJ
VARIDT Drug ID
DR00533
INTEDE Drug ID
DR1014
ACDINA Drug ID
D00390

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Phosphonate and phosphinate metabolism 1.73 3.65e-1 5/6 (83.33%) CHPT1;CEPT1
Fanconi anemia pathway 1.71 2.18e-1 36/54 (66.67%) FANCA;FANCI;REV1;...
PPAR signaling pathway 1.57 4.94e-1 66/74 (89.19%) FABP4;SCD5;PLIN1;...
Retinol metabolism 1.56 4.06e-1 41/68 (60.29%) UGT2B28;ADH1B;DHRS3;...
Regulation of lipolysis in adipocytes 1.54 3.55e-1 52/55 (94.55%) FABP4;PTGS2;PLIN1;...
ECM-receptor interaction 1.53 3.26e-1 80/88 (90.91%) ITGA6;SDC1;VWF;...
Nucleotide excision repair 1.51 3.36e-1 40/47 (85.11%) RAD23B;POLE;XPA;...
Homologous recombination 1.51 3.11e-1 35/41 (85.37%) SSBP1;RAD51D;RPA2;...
Peroxisome 1.50 2.89e-1 72/82 (87.8%) PEX11A;PXMP2;PEX16;...
Salivary secretion 1.49 2.82e-1 76/93 (81.72%) LYZ;CALML5;CST3;...
Bacterial invasion of epithelial cells 1.42 4.41e-1 59/77 (76.62%) SHC1;CDC42;CAV1;...
Hematopoietic cell lineage 1.42 4.19e-1 90/99 (90.91%) HLA-DRA;ITGA6;CD59;...
Spliceosome 1.38 4.97e-1 101/150 (67.33%) SRSF5;PRPF38B;SNRPD3;...
Staphylococcus aureus infection 1.38 4.71e-1 72/95 (75.79%) KRT14;KRT13;HLA-DRA;...
Cellular senescence 1.38 4.67e-1 139/156 (89.1%) E2F2;CXCL8;CALML5;...
Steroid hormone biosynthesis 1.37 4.40e-1 43/61 (70.49%) UGT2B28;HSD17B2;COMT;...
Other glycan degradation 1.33 5.43e-1 13/18 (72.22%) FUCA1;HEXB;HEXA;...
Herpes simplex virus 1 infection 1.33 5.33e-1 165/498 (33.13%) HLA-DRA;ITGB3;HLA-DPB1;...
Small cell lung cancer 1.31 5.61e-1 90/92 (97.83%) ITGA6;PTGS2;E2F2;...
Collecting duct acid secretion 1.30 5.68e-1 22/27 (81.48%) CA2;ATP6V1A;ATP6V1F;...
Folate biosynthesis 1.29 5.77e-1 23/26 (88.46%) ALPP;AKR1B1;AKR1B10;...
Cell adhesion molecules 1.29 5.80e-1 118/148 (79.73%) HLA-DRA;ITGA6;SDC1;...
Arachidonic acid metabolism 1.26 6.44e-1 48/61 (78.69%) PTGS2;PTGES;CBR3;...
Chronic myeloid leukemia 1.26 6.45e-1 72/76 (94.74%) E2F2;SHC1;CRKL;...
RNA transport 1.25 6.34e-1 128/186 (68.82%) EIF2S3;PNN;CYFIP1;...
Non-homologous end-joining 1.25 6.28e-1 11/13 (84.62%) XRCC5;DNTT;RAD50;...
Kaposi sarcoma-associated herpesvirus infection 1.24 6.20e-1 172/193 (89.12%) PTGS2;E2F2;CXCL8;...
Primary bile acid biosynthesis 1.23 6.47e-1 15/17 (88.24%) SCP2;AKR1C4;HSD17B4;...
IL-17 signaling pathway 1.19 6.73e-1 84/94 (89.36%) PTGS2;S100A9;CXCL8;...
Basal cell carcinoma 1.19 6.63e-1 41/63 (65.08%) FZD6;BAX;CTNNB1;...
beta-Alanine metabolism -1.17 7.71e-1 25/30 (83.33%) ALDH3B1;ALDH6A1;ACOX1;...
Leishmaniasis -1.18 7.37e-1 67/77 (87.01%) EEF1A2;IL1A;IFNG;...
Nicotinate and nicotinamide metabolism -1.18 7.25e-1 25/35 (71.43%) AOX1;SIRT2;SIRT5;...
Insulin signaling pathway -1.19 7.18e-1 121/137 (88.32%) PPP1CB;GSK3B;TRIP10;...
Insulin resistance -1.19 7.18e-1 96/108 (88.89%) PPP1CB;GSK3B;MLXIP;...
Renal cell carcinoma -1.19 7.34e-1 68/69 (98.55%) EP300;ARAF;RAF1;...
Proximal tubule bicarbonate reclamation -1.19 7.43e-1 21/23 (91.3%) GLS;ATP1B2;ATP1A1;...
Glycine, serine and threonine metabolism -1.20 7.48e-1 31/40 (77.5%) GNMT;DLD;SDS;...
Growth hormone synthesis, secretion and action -1.20 7.66e-1 108/119 (90.76%) GNAS;IGF1;GHRHR;...
Long-term depression -1.20 7.84e-1 55/60 (91.67%) MAP2K2;PPP1R17;PRKG2;...
Hypertrophic cardiomyopathy -1.20 7.71e-1 81/90 (90%) ITGB7;CACNG1;ATP2A1;...
Tuberculosis -1.21 7.74e-1 159/180 (88.33%) CREB1;RAB5A;CD14;...
T cell receptor signaling pathway -1.23 7.80e-1 93/104 (89.42%) MAPK10;MAP2K7;MAP2K1;...
Tryptophan metabolism -1.33 7.60e-1 35/42 (83.33%) EHHADH;DLD;KMO;...
Amoebiasis -1.34 7.37e-1 99/102 (97.06%) RAB5A;PRKACB;CD14;...
Pertussis -1.37 6.10e-1 64/76 (84.21%) C5;CASP7;IL1A;...
Natural killer cell mediated cytotoxicity -1.38 6.21e-1 99/131 (75.57%) MAP2K1;ZAP70;IFNAR1;...
Gap junction -1.40 5.52e-1 72/88 (81.82%) PRKACB;MAPK7;MAP2K1;...
Osteoclast differentiation -1.40 5.93e-1 117/127 (92.13%) CREB1;TYK2;TNFRSF11B;...
Endocytosis -1.40 6.36e-1 198/252 (78.57%) RAB31;CYTH2;PSD;...
Sulfur metabolism -1.41 6.59e-1 9/10 (90%) SUOX;ETHE1;SELENBP1;...
Cortisol synthesis and secretion -1.41 7.09e-1 58/65 (89.23%) POMC;PDE8A;GNAS;...
Alanine, aspartate and glutamate metabolism -1.42 7.48e-1 27/37 (72.97%) ASPA;GLS;GLUL;...
TGF-beta signaling pathway -1.46 6.25e-1 81/94 (86.17%) FBN1;INHBA;CDKN2B;...
JAK-STAT signaling pathway -1.46 7.10e-1 146/162 (90.12%) AOX1;IFNG;IL11RA;...
Fc epsilon RI signaling pathway -1.47 7.57e-1 57/68 (83.82%) MAPK10;MAP2K7;MAP2K1;...
Arginine and proline metabolism -1.50 7.52e-1 39/50 (78%) MAOB;AOC1;P4HA1;...
Steroid biosynthesis -1.53 7.79e-1 19/20 (95%) LSS;DHCR7;CYP51A1;...
Riboflavin metabolism -1.57 6.53e-1 7/8 (87.5%) BLVRB;ACP5;ENPP1
Histidine metabolism -1.79 1.68e-1 16/22 (72.73%) HDC;ALDH3B1;MAOB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293T CVCL_0063 Homo sapiens 0.125uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 15uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.125uM - 10uM 6H, 24H